Published in Vaccine Weekly, September 6th, 1999
HIV must use cellular chemokine receptors to infect cells. Natural chemokines block HIV infection. For several years, HIV co-discoverer Robert C. Gallo has advocated taking advantage of this fact by creating chemokine-based therapies.
Recently, Anthony DeVico, Gallo, and colleagues at the Institute of Human Virology showed that a novel chemokine known as macrophage-derived chemokine (MDC) can block infection by HIV strains that use either of the two chemokine receptors used for viral entry (CCR5 and CXCR4).
"Our more recent studies reveal that MDC is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.